• 1
    Cookson MS. Prostate cancer: screening and early detection. Cancer Control. 2001; 8: 133140.
  • 2
    Khan MA,Han M,Partin AW,Epstein JI,Walsh PC. Long-term cancer control of radical prostatectomy in men younger than 50 years of age: update 2003. Urology. 2003; 62: 8691.
  • 3
    Shipley WU,Thames HD,Sandler HM, et al. Radiation therapy for clinically localized prostate cancer: a multiinstitutional pooled analysis. JAMA. 1999; 281: 15981604.
  • 4
    Grossfeld GD,Li Y,Lubeck DP,Carroll PR. Patterns of failure after primary local therapy for prostate cancer and rationale for secondary therapy. Urology. 2002; 60( suppl 3A): 5762.
  • 5
    Mehta SS,Lubeck DP,Sadetsky N,Pasta DJ,Carroll PR. Patterns of secondary cancer treatment for biochemical failure following radical prostatectomy: data from CaPSURE. J Urol. 2004; 171: 215219.
  • 6
    Lubeck DP,Litwin MS,Henning JM, et al. The CaPSURE database: a methodology for clinical practice and research in prostate cancer. CaPSURE Research Panel. Cancer of the Prostate Strategic Urologic Research Endeavor. Urology. 1996; 48: 773777.
  • 7
    D'Amico AV,Whittington R,Malkowicz SB, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998; 280: 969974.
  • 8
    Jhaveri FM,Zippe CD,Klein EA,Kupelian PA. Biochemical failure does not predict overall survival after radical prostatectomy for localized prostate cancer: 10-year results. Urology. 1999; 54: 884890.
  • 9
    Pound CR,Partin AW,Eisenberger MA,Chan DW,Pearson JD,Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. JAMA. 1999; 281: 16421645.
  • 10
    Ward JF,Blute ML,Slezak J,Bergstralh EJ,Zincke H. The long-term clinical impact of biochemical recurrence of prostate cancer 5 or more years after radical prostatectomy. J Urol. 2003; 170: 18721876.
  • 11
    Khuntia D,Reddy CA,Mahadevan A,Klein EA,Kupelian PA. Recurrence-free survival rates after external beam radiotherapy for patients with clinical T1-T3 prostate carcinoma in the prostate-specific antigen era: what should we expect? Cancer. 2004; 6: 12831292.
  • 12
    Zagars GK,Pollack A,von Eschenbach AC. Prognostic factors for clinically localized prostate carcinoma: analysis of 938 patients irradiated in the prostate specific antigen era. Cancer. 1997; 79: 13701380.
  • 13
    D'Amico AV,Schultz D,Loffredo M, et al. Biochemical outcome following external beam radiation therapy with or without androgen suppression therapy for clinically localized prostate cancer. JAMA. 2000; 284: 12801283.
  • 14
    Bolla M,Gonazalez D,Warde P, et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med. 1997; 337: 295300.
  • 15
    Terai A,Matsui Y,Yoshimura K,Arai Y,Dodo Y. Salvage radiotherapy for biochemical recurrence after radical prostatectomy. BJU Int. 2005; 96: 10091013.
  • 16
    Stephenson AJ,Shariat SF,Zelefsky MJ, et al. Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy. JAMA. 2004; 291: 13251332.
  • 17
    Sanderson KM,Penson DF,Cai J, et al. Salvage radical prostatectomy: quality of life outcomes and long-term oncological control of radiorecurrent prostate cancer. J Urol. 2006; 176: 20252031.
  • 18
    Izawa JI,Madsen LT,Scott SM, et al. Salvage cryotherapy for recurrent prostate cancer after radiotherapy: variables affecting patient outcome. J Clin Oncol. 2002; 20: 26642671.
  • 19
    Horwitz EM,Thames HD,Kuban DA, et al. Definitions of biochemical failure that best predict clinical failure in patients with prostate cancer treated with external beam radiation alone: a multi-institutional pooled analysis. J Urol. 2005; 173: 797802.